ArticleJournal of clinical microbiology2005
Activities of available and investigational antifungal agents against rhodotorula species.
Article in Journal of clinical microbiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Intra-abdominal abscess caused by Rhodotorula mucilaginosa in a peritoneal dialysis patient: a case report.CEN case reports · 2026Article
- Review
- Article
- First reportedClinical case reports · 2023Article
- Article
- Article
- Antifungal Susceptibility Testing: A Primer for Clinicians.Open forum infectious diseases · 2021Review
- All You Need To Know and More about the Diagnosis and Management of Rare Yeast Infections.mBio · 2021Article
- Central line-associatedClinical case reports · 2021Article
- Along came a spider: an unusual organism identified in a peritoneal dialysis patient, a case report and literature review.BMC nephrology · 2020Article
- Molecular identification, biofilm formation and antifungal susceptibility of Rhodotorula spp.Molecular biology reports · 2020Article
- Article
- In Vitro Interactions of Amphotericin B Combined with Non-antifungal Agents Against Rhodotorula mucilaginosa Strains.Mycopathologia · 2019Article
- Rhodotorula spp. in the gut - foe or friend?GMS infectious diseases · 2019Review
- Risk of Fungal Infection to Dental Patients.TheScientificWorldJournal · 2017Article
- Rare fungal infectious agents: a lurking enemy.F1000Research · 2017Review
- Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015Article
- Rhodotorula mucilaginosa associacted meningitis: A subacute entity with high mortality. Case report and review.Medical mycology case reports · 2014Article
- A Case of Onychomycosis Caused by Rhodotorula glutinis.Case reports in dermatological medicine · 2014Article
- Endocarditis caused by Rhodotorula infection.Journal of clinical microbiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhodotorula species are emerging pathogens in immunocompromised patients. We report the in vitro activities of eight antifungals against 64 Rhodotorula isolates collected in surveillance programs between 1987 and 2003. Rhodotorula strains are resistant in vitro to fluconazole (MIC at which 50% of the isolates tested are inhibited [MIC(50)], >128 microg/ml) and caspofungin (MIC(50), >8 microg/ml). Amphotericin B (MIC(50),1 microg/ml) and flucytosine (MIC(50), 0.12 microg/ml) are both active in vitro, and the new and investigational triazoles all have some in vitro activity, with ravuconazole being the most active (MIC(50), 0.25 microg/ml).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.